Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

N/ACompletedNCT03496844

University of Arizona15 enrolled

Overview

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Prostate Adenocarcinoma

Interventions

F-18 fluciclovine-PET/CT scanDIAGNOSTIC_TEST

PET/CT imaging with F-18 fluciclovine

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male 2. Be ≥ 18 years of age 3. Diagnosed with prostate cancer 4. Be willing and able to provide informed consent 5. Be informed of the investigational nature of this study Exclusion Criteria: 1. Having a history of severe claustrophobia 2. Weight exceeding 400lbs

Locations (1)

University of Arizona

Tucson, Arizona, United States

Outcomes

Primary Outcomes

True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy

True positive and false positive rates of positive findings in the skeleton on F-18 fluciclovine-PET/CT scan compared to gold standard pathology from bone biopsy

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.